<p>ALT5 Sigma（納斯達克代碼：ALTS - 獲取免費報告）在週六發佈的研究報告中被華爾街 Zen 的投資分析師從 “賣出” 評級下調至 “強烈賣出” 評級。</p>
<p>另外，Weiss Ratings 在 12 月 29 日的報告中重申了對 ALT5 Sigma 股票的 “賣出（d-）” 評級。根據 MarketBeat 的數據顯示，一位分析師對該股票給予了賣出評級，ALT5 Sigma 的共識評級為 “賣出”。</p>
<p><strong>閲讀我們對 ALTS 的最新分析</strong></p>
<h2>ALT5 Sigma 上漲 2.4%</h2>
<p>週五，納斯達克 ALTS 的開盤價為 0.98 美元。該公司的債務與股本比率為 0.01，流動比率為 0.79，速動比率為 0.79。ALT5 Sigma 的 12 個月低點為 0.87 美元，12 個月高點為 10.95 美元。該公司的 50 日簡單移動平均線為 1.31 美元，200 日簡單移動平均線為 1.72 美元。</p>
<p>ALT5 Sigma（納斯達克代碼：ALTS - 獲取免費報告）最後一次發佈財報是在 4 月 11 日，報告顯示該季度每股收益（EPS）為（6.19 美元）。該季度的收入為 537 萬美元。ALT5 Sigma 的淨利潤率為 133.06%，股本回報率為 8.60%。</p>
<h2>ALT5 Sigma 的機構交易</h2>
<p>幾家對沖基金最近調整了對 ALTS 的持股。Balyasny Asset Management L.P.在第四季度購買了 ALT5 Sigma 的新股份，價值約為 26,000 美元。Arete Wealth Advisors LLC 在第三季度購買了 ALT5 Sigma 的新股份，價值約為 28,000 美元。Profund Advisors LLC 在第三季度購買了 ALT5 Sigma 的新股份，價值約為 28,000 美元。Victory Capital Management Inc.在第三季度購買了 ALT5 Sigma 的新股份，價值約為 33,000 美元。最後，First Citizens Bank &amp; Trust Co.在第三季度購買了 ALT5 Sigma 的新股份，價值約為 35,000 美元。6.27% 的股票由機構投資者持有。</p>
<h2>關於 ALT5 Sigma</h2>
<p>（獲取免費報告）</p>
<p>ALT5 Sigma Corp.是一家臨牀階段的生物製藥公司，專注於識別、收購、許可、開發、合作和商業化新型非阿片類和非成癮性療法，以滿足對疼痛和成癮治療的巨大未滿足醫療需求。它在生物技術和回收兩個領域運營。生物技術部門專注於尋找治療導致嚴重疼痛的疾病的療法，並將具有非成癮性止痛特性的藥物推向市場。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 ALT5 Sigma</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 ALT5 Sigma 嗎？</h2>
<p>在你考慮 ALT5 Sigma 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 ALT5 Sigma 並不在名單上。</p>
<p>雖然 ALT5 Sigma 目前在分析師中被評為賣出評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ALTS

2 倍做多納斯達克生物技術 ETF - ProShares

醫藥突破 ETF - ALPS

<p>華爾街禪將 ALT5 Sigma（NASDAQ:ALTS）的評級從 “賣出” 下調至 “強烈賣出”。該公司報告的淨利潤率為 133.06%，股本回報率為 8.60%，最近的交易價格為 0.98 美元。機構投資者持有該股票的 6.27%。該公司專注於開發非阿片類的疼痛和成癮治療方法。儘管評級下調，一些分析師認為其他股票可能是更好的投資選擇</p>

<p>ALT5 Sigma (NASDAQ:ALTS - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a &#34;sell&#34; rating to a &#34;strong sell&#34; rating in a research report issued on Saturday.</p>
<div class="lb-trans"><p>ALT5 Sigma（納斯達克代碼：ALTS - 獲取免費報告）在週六發佈的研究報告中被華爾街 Zen 的投資分析師從 “賣出” 評級下調至 “強烈賣出” 評級。</p>
</div><p>Separately, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of ALT5 Sigma in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, ALT5 Sigma has a consensus rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 12 月 29 日的報告中重申了對 ALT5 Sigma 股票的 “賣出（d-）” 評級。根據 MarketBeat 的數據顯示，一位分析師對該股票給予了賣出評級，ALT5 Sigma 的共識評級為 “賣出”。</p>
</div><p><strong>Read Our Latest Analysis on ALTS</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 ALTS 的最新分析</strong></p>
</div><h2>ALT5 Sigma Trading Up 2.4%</h2>
<div class="lb-trans"><h2>ALT5 Sigma 上漲 2.4%</h2>
</div><p>NASDAQ ALTS opened at $0.98 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.79 and a quick ratio of 0.79. ALT5 Sigma has a twelve month low of $0.87 and a twelve month high of $10.95. The company's 50-day simple moving average is $1.31 and its 200 day simple moving average is $1.72.</p>
<div class="lb-trans"><p>週五，納斯達克 ALTS 的開盤價為 0.98 美元。該公司的債務與股本比率為 0.01，流動比率為 0.79，速動比率為 0.79。ALT5 Sigma 的 12 個月低點為 0.87 美元，12 個月高點為 10.95 美元。該公司的 50 日簡單移動平均線為 1.31 美元，200 日簡單移動平均線為 1.72 美元。</p>
</div><p>ALT5 Sigma (NASDAQ:ALTS - Get Free Report) last posted its earnings results on Saturday, April 11th. The company reported ($6.19) earnings per share (EPS) for the quarter. The firm had revenue of $5.37 million during the quarter. ALT5 Sigma had a net margin of 133.06% and a return on equity of 8.60%.</p>
<div class="lb-trans"><p>ALT5 Sigma（納斯達克代碼：ALTS - 獲取免費報告）最後一次發佈財報是在 4 月 11 日，報告顯示該季度每股收益（EPS）為（6.19 美元）。該季度的收入為 537 萬美元。ALT5 Sigma 的淨利潤率為 133.06%，股本回報率為 8.60%。</p>
</div><h2>Institutional Trading of ALT5 Sigma</h2>
<div class="lb-trans"><h2>ALT5 Sigma 的機構交易</h2>
</div><p>Several hedge funds have recently modified their holdings of ALTS. Balyasny Asset Management L.P. bought a new stake in shares of ALT5 Sigma during the fourth quarter valued at approximately $26,000. Arete Wealth Advisors LLC bought a new stake in shares of ALT5 Sigma during the third quarter valued at approximately $28,000. Profund Advisors LLC bought a new stake in shares of ALT5 Sigma during the third quarter valued at approximately $28,000. Victory Capital Management Inc. bought a new stake in shares of ALT5 Sigma during the third quarter valued at approximately $33,000. Finally, First Citizens Bank &amp; Trust Co. bought a new stake in shares of ALT5 Sigma during the third quarter valued at approximately $35,000. 6.27% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>幾家對沖基金最近調整了對 ALTS 的持股。Balyasny Asset Management L.P.在第四季度購買了 ALT5 Sigma 的新股份，價值約為 26,000 美元。Arete Wealth Advisors LLC 在第三季度購買了 ALT5 Sigma 的新股份，價值約為 28,000 美元。Profund Advisors LLC 在第三季度購買了 ALT5 Sigma 的新股份，價值約為 28,000 美元。Victory Capital Management Inc.在第三季度購買了 ALT5 Sigma 的新股份，價值約為 33,000 美元。最後，First Citizens Bank &amp; Trust Co.在第三季度購買了 ALT5 Sigma 的新股份，價值約為 35,000 美元。6.27% 的股票由機構投資者持有。</p>
</div><h2>About ALT5 Sigma</h2>
<div class="lb-trans"><h2>關於 ALT5 Sigma</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.</p>
<div class="lb-trans"><p>ALT5 Sigma Corp.是一家臨牀階段的生物製藥公司，專注於識別、收購、許可、開發、合作和商業化新型非阿片類和非成癮性療法，以滿足對疼痛和成癮治療的巨大未滿足醫療需求。它在生物技術和回收兩個領域運營。生物技術部門專注於尋找治療導致嚴重疼痛的疾病的療法，並將具有非成癮性止痛特性的藥物推向市場。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than ALT5 Sigma</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 ALT5 Sigma</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in ALT5 Sigma Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 ALT5 Sigma 嗎？</h2>
</div><p>Before you consider ALT5 Sigma, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 ALT5 Sigma 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ALT5 Sigma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 ALT5 Sigma 並不在名單上。</p>
</div><p>While ALT5 Sigma currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 ALT5 Sigma 目前在分析師中被評為賣出評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

ALT5 Sigma（NASDAQ: ALTS）在 Wall Street Zen 被下調至 “強烈賣出” 評級